Drug Approval | March 28, 2022
EU approves Evusheld to prevent Covid-19
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Clinical trials for minimally invasive therapy procedures using advanced imaging from Philips Lung Suite start with successful first cases
These courses are for pre-selected candidates who have completed their MBBS with an additional 2 years of surgical experience training
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies
The new glass-free detector has improved durability, is more reliable, and has an improved rugged design to sustain in a high workload environment
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
Submissions for Ruminant Well-Being Awards and Gustav Rosenberger Memorial Fund grant open now
Sputnik Light is the first component of Sputnik V
Augnito in association with Japanese company Fujifilm enables voice recognition within their radiology information system platform
Subscribe To Our Newsletter & Stay Updated
